Literature DB >> 12235254

Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.

Peter Milberg1, Lars Eckardt, Hans-Jürgen Bruns, Julia Biertz, Shahram Ramtin, Nico Reinsch, Dirk Fleischer, Paulus Kirchhof, Larissa Fabritz, Günter Breithardt, Wilhelm Haverkamp.   

Abstract

Macrolide antibiotics are known to have a different proarrhythmic potential in the presence of comparable QT prolongation in the surface ECG. Because the extent of QT prolongation has been used as a surrogate marker for cardiotoxicity, we aimed to study the different electrophysiological effects of the macrolide antibiotics erythromycin, clarithromycin, and azithromycin in a previously developed experimental model of proarrhythmia. In 37 Langendorff-perfused rabbit hearts, erythromycin (150-300 microM, n = 13) clarithromycin (150-300 microM, n = 13), and azithromycin (150-300 microM, n = 11) led to similar increases in QT interval and monophasic action potential (MAP) duration. In bradycardic (atrioventricular-blocked) hearts, eight simultaneously recorded epi- and endocardial MAPs demonstrated increased dispersion of repolarization in the presence of all three antibiotics. Erythromycin and clarithromycin led to early afterdepolarizations (EADs) and torsade de pointes (TdP) after lowering of potassium concentration. In the presence of azithromycin, no EAD or TdP occurred. Erythromycin and clarithromycin changed the MAP configuration to a triangular pattern, whereas azithromycin caused a rectangular pattern of MAP prolongation. In 13 additional hearts, 150 microM azithromycin was administered after previous treatment with 300 microM erythromycin and suppressed TdP provoked by erythromycin. In conclusion, macrolide antibiotics lead to similar prolongation of repolarization but show a different proarrhythmic potential (erythromycin > clarithromycin > azithromycin). In the presence of azithromycin, neither EAD nor TdP occur. This effect may be related to a rectangular pattern of action potential prolongation, whereas erythromycin and clarithromycin cause triangular action potential prolongation and induce TdP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12235254     DOI: 10.1124/jpet.102.037911

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  59 in total

1.  A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes.

Authors:  C L Lawrence; M H Bridgland-Taylor; C E Pollard; T G Hammond; J-P Valentin
Journal:  Br J Pharmacol       Date:  2006-10-09       Impact factor: 8.739

Review 2.  Gastroparesis: current diagnostic challenges and management considerations.

Authors:  Shamaila Waseem; Baharak Moshiree; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

3.  Blockade of I(Ca) suppresses early afterdepolarizations and reduces transmural dispersion of repolarization in a whole heart model of chronic heart failure.

Authors:  P Milberg; M Fink; C Pott; G Frommeyer; J Biertz; N Osada; J Stypmann; G Mönnig; M Koopmann; G Breithardt; L Eckardt
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 4.  Drug-induced QT prolongation and sudden death.

Authors:  Marc E Del Rosario; Richard Weachter; Greg C Flaker
Journal:  Mo Med       Date:  2010 Jan-Feb

5.  Risk of cardiovascular effects with azithromycin.

Authors:  Ramachandran Kumaresan; Subish Palaian; Santosh Thapa; Pathiyil Ravi Shankar
Journal:  J Clin Diagn Res       Date:  2015-01-01

6.  Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias.

Authors:  Franck Potet; Amanda N Lorinc; Sebastien Chaigne; Corey R Hopkins; Raghav Venkataraman; Svetlana Z Stepanovic; L Michelle Lewis; Emily Days; Veniamin Y Sidorov; Darren W Engers; Beiyan Zou; David Afshartous; Alfred L George; Courtney M Campbell; Jeffrey R Balser; Min Li; Franz J Baudenbacher; Craig W Lindsley; C David Weaver; Sabina Kupershmidt
Journal:  J Biol Chem       Date:  2012-10-02       Impact factor: 5.157

Review 7.  Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Chiara Zuliani; Arno Muller; Herman Goossens; Fabrizio De Ponti
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

Review 8.  Cardiac risks associated with antibiotics: azithromycin and levofloxacin.

Authors:  Zhiqiang Kevin Lu; Jing Yuan; Minghui Li; S Scott Sutton; Gowtham A Rao; Sony Jacob; Charles L Bennett
Journal:  Expert Opin Drug Saf       Date:  2014-12-10       Impact factor: 4.250

9.  Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance.

Authors:  Luigi X Cubeddu
Journal:  Curr Cardiol Rev       Date:  2009-08

Review 10.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.